Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Boundless Bio Inc (BOLD)

Boundless Bio Inc (BOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,520
  • Shares Outstanding, K 22,386
  • Annual Sales, $ 0 K
  • Annual Income, $ -65,360 K
  • EBIT $ -68 M
  • EBITDA $ -67 M
  • 60-Month Beta -0.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.38
  • Number of Estimates 1
  • High Estimate -0.38
  • Low Estimate -0.38
  • Prior Year -0.71
  • Growth Rate Est. (year over year) +46.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +4.55%
on 02/12/26
1.2000 -4.17%
on 02/25/26
+0.0300 (+2.68%)
since 02/10/26
3-Month
0.9612 +19.64%
on 02/05/26
1.3700 -16.06%
on 12/18/25
-0.0100 (-0.86%)
since 12/10/25
52-Week
0.9612 +19.64%
on 02/05/26
1.7900 -35.75%
on 03/13/25
-0.4800 (-29.45%)
since 03/10/25

Most Recent Stories

More News
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1...

BOLD : 1.1500 (+0.88%)
Boundless Bio to Participate in the Leerink Global Healthcare Conference

SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...

BOLD : 1.1500 (+0.88%)
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...

BOLD : 1.1500 (+0.88%)
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

BBI-940 IND accepted; initiation of first-in-human clinical trial on track  for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating...

BOLD : 1.1500 (+0.88%)
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...

BOLD : 1.1500 (+0.88%)
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

 Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate...

BOLD : 1.1500 (+0.88%)
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...

BOLD : 1.1500 (+0.88%)
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of...

BOLD : 1.1500 (+0.88%)
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BOLD : 1.1500 (+0.88%)
Boundless Bio Announces Portfolio Prioritization and Runway Extension

BOLD : 1.1500 (+0.88%)

Business Summary

Boundless Bio Inc. is a clinical stage oncology company interrogating extrachromosomal DNA biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers. Boundless Bio Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 1.2117
2nd Resistance Point 1.1933
1st Resistance Point 1.1717
Last Price 1.1500
1st Support Level 1.1317
2nd Support Level 1.1133
3rd Support Level 1.0917

See More

52-Week High 1.7900
Fibonacci 61.8% 1.4734
Fibonacci 50% 1.3756
Fibonacci 38.2% 1.2778
Last Price 1.1500
52-Week Low 0.9612

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar